title: Calciphylaxis: a systematic review of existing and emerging therapies.
abstract: Calciphylaxis, also known as calcific uremic arteriolopathy, is a cutaneous ischemic small vessel vasculopathy seen in 1 to 4% of patients with chronic kidney disease on hemodialysis. It is associated with extreme pain and a 60 to 80% mortality rate in the setting of few and frequently ineffective therapeutic options, although this may be changing based on reports of success with newer therapies.
authors.affiliation: Harvard Medical School, Boston, Massachusetts 02115, USA. chetan@post.harvard.edu
authors.forename: Chetan
authors.initials: C
authors.lastname: Vedvyas
authors.forename: Laura S
authors.initials: LS
authors.lastname: Winterfield
authors.forename: Ruth Ann
authors.initials: RA
authors.lastname: Vleugels
mesh_terms: D000975:Antioxidants / Q000627:therapeutic use; D002115:Calciphylaxis / Q000628:therapy*; D000069449:Cinacalcet; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D009281:Naphthalenes / Q000627:therapeutic use; D016105:Parathyroidectomy; D017445:Skin Diseases, Vascular / Q000628:therapy*; D013885:Thiosulfates / Q000627:therapeutic use
chemical_list: D000975:Antioxidants; D004164:Diphosphonates; D009281:Naphthalenes; D013885:Thiosulfates; C017717:sodium thiosulfate; D000069449:Cinacalcet